CD274 and non-small cell lung carcinoma: Studies on atezolizumab, another ICI approved for the treatment of NSCLC, have also demonstrated little difference between atezolizumab monotherapy and combination therapy among patients with high PD‐L1 expression.10, 11, 15, 16, 17